Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 13/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | PHPT1 | Q9NRX4 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952367 | 0.85 | POLB (0.67) | KCNMA1POLBKDM4EHSD17B10LMNA | |
| SCHEMBL3782005 | 0.84 | KDM4E (0.68) | POLBKDM4EHSD17B10SMN1; SMN2HDAC1 | |
| SCHEMBL28295632 | 0.84 | KCNMA1 (0.68) | KCNMA1POLBMEN1HPGDKMT2A | |
| SCHEMBL6814424 | 0.83 | ALDH1A1 (0.56) | KCNMA1POLBKDM4ELMNAHDAC1 | |
| SCHEMBL2388970 | 0.82 | EPHX1 (0.70) | POLBKDM4EHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL9170975 | 0.82 | POLB (0.71) | KCNMA1POLBMEN1HPGDKMT2A | |
| SCHEMBL8983170 | 0.82 | KCNMA1 (0.57) | KCNMA1POLBKDM4ELMNASMN1; SMN2 | |
| SCHEMBL7254163 | 0.81 | KCNMA1 (0.60) | KCNMA1POLBKDM4ELMNASMN1; SMN2 | |
| SCHEMBL7254652 | 0.81 | KCNMA1 (0.61) | KCNMA1POLBKDM4ELMNASMN1; SMN2 | |
| SCHEMBL9403860 | 0.81 | KDM4E (0.59) | KCNMA1POLBKDM4EHSD17B10HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5149858-A | Reacting with chlorine gas in presence of organic cation catalysts | RHONE-POULENC CHIMIE (FR) | 1992-09-22 | — | — | US | claimed |
| EP-0299891-B1 | PROCESS FOR THE SELECTIVE CHLORINATION OF PHENOLIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1991-12-11 | — | — | EP | claimed |
| CN-105753730-A | Method for preparing 2-amino-4-chloro-5-nitrophenol | 宜兴市新宇化工有限公司 | 2016-07-13 | — | — | CN | disclosed |
| EP-1246792-B1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20110200687-A1 | BIFEPRUNOX MESYLATE MAINTENANCE DOSE COMPOSITIONS AND METHODS FOR USING THE SAME | SOLVAY PHARMACEUTICALS B.V. | 2011-08-18 | — | — | US | disclosed |
| US-7977506-B2 | Amino acid for delivering active materials; bioavailability | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7964604-B2 | Bifeprunox mesylate maintenance dose compositions and methods for using the same | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-1656358-B1 | STABLE POLYMORPH OF BIFEPRUNOX MESILATE | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-02-23 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1853232-B1 | STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESYLATE, DOSAGE FORMS THEREOF ADN METHODS FOR USING THEM | SOLVAY PHARM BV (NL) | 2009-08-19 | — | — | EP | disclosed |
| WO-1998007724-A1 | PROCESS FOR THE PREPARATION OF 7-ALKOXYALKYL-1,2,4-TRIAZOLO[1,5-A] PYRIMIDINE DERIVATIVES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| US-5149858-A | Reacting with chlorine gas in presence of organic cation catalysts | RHONE-POULENC CHIMIE (FR) | 1992-09-22 | — | — | US | disclosed |
| EP-0006220-B1 | PROCESS FOR THE PREPARATION OF 3-ACYL-2-ALKYL(ARYL)-1.3.2-BENZOXAZAPHOSPHOLANES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-19 | — | — | EP | disclosed |
| EP-0006195-B1 | PROCESS FOR PREPARING DELTA-3 1-OXOPHOSPHOLENES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-05-13 | — | — | EP | disclosed |
| US-4263231-A | REACTING DICHLOROPHOSPHANES AND 2-N-ACYLAMINOPHENOLS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | disclosed |
| US-4247488-A | Process for the preparation of 1-oxophosphol-Δ3 -enes | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| EP-0006195-A1 | Process for preparing delta-3 1-oxophospholenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-09 | — | — | EP | disclosed |
| EP-0006220-A1 | Process for the preparation of 3-Acyl-2-alkyl(aryl)-1.3.2-benzoxazaphospholanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-09 | — | — | EP | disclosed |
| US-4112117-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200687-A1 | BIFEPRUNOX MESYLATE MAINTENANCE DOSE COMPOSITIONS AND METHODS FOR USING THE SAME | LPXN, TPMT, MC2R | KCNMA1 2895/4885POLB 3419/4885KDM4E 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.